Colitis and Crohn’s Foundation (India) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease

Despite several recent advances in therapy in inflammatory bowel disease (IBD), 5-aminosalicylic acid (5-ASA) therapy has retained its place especially in ulcerative colitis. This consensus on 5-ASA is obtained through a modified Delphi process, and includes guiding statements and recommendations ba...

Descripción completa

Detalles Bibliográficos
Autores principales: Sood, Ajit, Ahuja, Vineet, Midha, Vandana, Sinha, Saroj Kant, Pai, C. Ganesh, Kedia, Saurabh, Mehta, Varun, Bopanna, Sawan, Abraham, Philip, Banerjee, Rupa, Bhatia, Shobna, Chakravartty, Karmabir, Dadhich, Sunil, Desai, Devendra, Dwivedi, Manisha, Goswami, Bhabhadev, Kaur, Kirandeep, Khosla, Rajeev, Kumar, Ajay, Mahajan, Ramit, Misra, S. P., Peddi, Kiran, Singh, Shivaram Prasad, Singh, Arshdeep
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Association for the Study of Intestinal Diseases 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7609395/
https://www.ncbi.nlm.nih.gov/pubmed/32646198
http://dx.doi.org/10.5217/ir.2019.09176
Descripción
Sumario:Despite several recent advances in therapy in inflammatory bowel disease (IBD), 5-aminosalicylic acid (5-ASA) therapy has retained its place especially in ulcerative colitis. This consensus on 5-ASA is obtained through a modified Delphi process, and includes guiding statements and recommendations based on literature evidence (randomized trials, and observational studies), clinical practice, and expert opinion on use of 5-ASA in IBD by Indian gastroenterologists. The aim is to aid practitioners in selecting appropriate treatment strategies and facilitate optimal use of 5-ASA in patients with IBD.

Ejemplares similares